Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells

Cancer Letters

Volumn 314, Issue 1, 2012, Pages 8-23

  Zhao, Jing ^a,b   Lu, Yixin ^b   Shen, Han Ming ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Cancer; P53; Sensitization; TRAIL

Indexed keywords

ANDROGRAPHOLIDE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CONATUMUMAB; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DULANERMIN; ETOPOSIDE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLUOROURACIL; IRINOTECAN; LEXATUMUMAB; MAPATUMUMAB; METHOTREXATE; NIMBOLIDE; OSTEOPROTEGERIN; PACLITAXEL; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RESVERATROL; TIGATUZUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR AGONIST; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN;

APOPTOSIS; CANCER CELL; CANCER CELL CULTURE; CELL ACTIVITY; CELL STRESS; CHEMOSENSITIVITY; COLORECTAL CANCER; DNA REPAIR; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; FRAMESHIFT MUTATION; GENE MUTATION; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MISSENSE MUTATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONSENSE MUTATION; OVARY CANCER; P53 GENE; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WILD TYPE;

EID: 82355180992     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.09.040     Document Type: Review

References (217)

1. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
2. Ichikawa K., Liu W.M., Wang Z., Liu D., Zhao L.M., Zhang H.G., Mountz J.D., Koopman W.J., Kimberley R.P., Zhou T. Tumoricidal activity in the absence of hepatocyte cytotoxicity of a novel anti-human DR5 monoclonal antibody. Faseb. J. 2001, 15:A1198.
3. Stieglmaier J., Bremer E., Kellner C., Liebig T.M., ten Cate B., Peipp M., Schulze-Koops H., Pfeiffer M., Buhring H.J., Greil J., Oduncu F., Emmerich B., Fey G.H., Helfrich W. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother. 2008, 57:233-246.
4. Griffith T.S., Rauch C.T., Smolak P.J., Waugh J.Y., Boiani N., Lynch D.H., Smith C.A., Goodwin R.G., Kubin M.Z. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol. 1999, 162:2597-2605.
5. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
6. Dyer M.J., MacFarlane M., Cohen G.M. Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol. 2007, 25:4505-4506.
7. Siegelin M.D., Reuss D.E., Habel A., Rami A., von Deimling A. Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. Neuro Oncol. 2009, 11:122-131.
8. Whitson E.L., Thomas C.L., Henrich C.J., Sayers T.J., McMahon J.B., McKee T.C. Clerodane diterpenes from Casearia arguta that act as synergistic TRAIL sensitizers. J. Nat. Prod. 2010, 73:2013-2018.
9. Morizot A., Merino D., Lalaoui N., Jacquemin G., Granci V., Iessi E., Lanneau D., Bouyer F., Solary E., Chauffert B., Saas P., Garrido C., Micheau O. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ. 2011, 18:700-711.
10. Jane E.P., Premkumar D.R., Pollack I.F. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol. Cancer Ther. 2011, 10:198-208.
11. Leong S., Cohen R.B., Gustafson D.L., Langer C.J., Camidge D.R., Padavic K., Gore L., Smith M., Chow L.Q., von Mehren M., O'Bryant C., Hariharan S., Diab S., Fox N.L., Miceli R., Eckhardt S.G. Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 2009, 27:4413-4421.
12. Soria J.C., Smit E., Khayat D., Besse B., Yang X., Hsu C.P., Reese D., Wiezorek J., Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel Carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1527-1533.
13. Laptenko O., Prives C. Transcriptional regulation by p53: one protein Many possibilities. Cell Death Differ. 2006, 13:951-961.
14. Chumakov P.M. Versatile functions of p53 protein in multicellular organisms. Biochemistry (Mosc.) 2007, 72:1399-1421.
15. Menendez D., Inga A., Resnick M.A. The expanding universe of p53 targets. Nat. Rev. Cancer 2009, 9:724-737.
16. Fischer U., Schulze-Osthoff K. Apoptosis-based therapies and drug targets. Cell Death Differ. 2005, 12(Suppl 1):942-961.
17. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., Smith C.A., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682.
18. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
19. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5 a new member of the TNFR family and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997, 7:821-830.
20. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., Timour M.S., Gerhart M.J., Schooley K.A., Smith C.A., Goodwin R.G., Rauch C.T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 1997, 16:5386-5397.
21. Schneider P., Bodmer J.L., Thome M., Hofmann K., Holler N., Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett. 1997, 416:329-334.
22. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 1997, 272:25417-25420.
23. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis yet retains an incomplete death domain. Immunity 1997, 7:813-820.
24. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., Yuan J., Gurney A., Goddard A.D., Godowski P., Ashkenazi A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 1997, 7:1003-1006.
25. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., Dul E., Appelbaum E.R., Eichman C., DiPrinzio R., Dodds R.A., James I.E., Rosenberg M., Lee J.C., Young P.R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 1998, 273:14363-14367.
26. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C., McLaughlin M.M., Srinivasula S.M., Livi G.P., Marshall L.A., Alnemri E.S., Williams W.V., Doyle M.L. Temperature-sensitive differential affinity of TRAIL for its receptors DR5 is the highest affinity receptor. J. Biol. Chem. 2000, 275:23319-23325.
27. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J., Debatin K.M., Krammer P.H., Peter M.E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998, 17:1675-1687.
28. Gonzalvez F., Ashkenazi A. New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene 2010, 29:4752-4765.
29. Li H., Zhu H., Xu C.J., Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998, 94:491-501.
30. Bagnoli M., Canevari S., Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int. J. Biochem. Cell Biol. 2010, 42:210-213.
31. Kataoka T. The caspase-8 modulator c-FLIP. Crit. Rev. Immunol. 2005, 25:31-58.
32. Tait S.W., Green D.R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 2010, 11:621-632.
33. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M., Alnemri E.S., Salvesen G.S., Reed J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17:2215-2223.
34. Griffith T.S., Fialkov J.M., Scott D.L., Azuhata T., Williams R.D., Wall N.R., Altieri D.C., Sandler A.D. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res. 2002, 62:3093-3099.
35. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 2006, 26:7046-7055.
36. Abdulghani J., El-Deiry W.S. TRAIL receptor signaling and therapeutics. Expert Opin. Ther. Targets 2010, 14:1091-1108.
37. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
38. Rossin A., Derouet M., Abdel-Sater F., Hueber A.O. Palmitoylation of the TRAIL receptor DR4 confers an efficient TRAIL-induced cell death signalling. Biochem. J. 2009, 419:185-192. (182p following 192).
39. Garofalo M., Quintavalle C., Di Leva G., Zanca C., Romano G., Taccioli C., Liu C.G., Croce C.M., Condorelli G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008, 27:3845-3855.
40. Ozaki T., Nakagawara A. P53: the attractive tumor suppressor in the cancer research field. J. Biomed. Biotechnol. 2011, 2011:603925.
41. Veprintsev D.B., Freund S.M., Andreeva A., Rutledge S.E., Tidow H., Canadillas J.M., Blair C.M., Fersht A.R. Core domain interactions in full-length p53 in solution. Proc. Natl. Acad. Sci., USA 2006, 103:2115-2119.
42. Joerger A.C., Fersht A.R. Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 2007, 26:2226-2242.
43. Piette J., Neel H., Marechal V. Mdm2: keeping p53 under control. Oncogene 1997, 15:1001-1010.
44. Momand J., Wu H.H., Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000, 242:15-29.
45. Thut C.J., Chen J.L., Klemm R., Tjian R. P53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995, 267:100-104.
46. Lu H., Levine A.J. Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc. Natl. Acad. Sci., USA 1995, 92:5154-5158.
47. Gu W., Shi X.L., Roeder R.G. Synergistic activation of transcription by CBP and p53. Nature 1997, 387:819-823.
48. Grossman S.R. P300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 2001, 268:2773-2778.
49. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci., USA 1996, 93:15335-15340.
50. Muller-Tiemann B.F., Halazonetis T.D., Elting J.J. Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. Proc. Natl. Acad. Sci., USA 1998, 95:6079-6084.
51. Joerger A.C., Fersht A.R. The tumor suppressor p53: from structures to drug discovery. Cold Spring Harbor Perspect. Biol. 2010, 2:a000919.
52. Weinberg R.L., Freund S.M., Veprintsev D.B., Bycroft M., Fersht A.R. Regulation of DNA binding of p53 by its C-terminal domain. J. Mol. Biol. 2004, 342:801-811.
53. Friedler A., Veprintsev D.B., Freund S.M., von Glos K.I., Fersht A.R. Modulation of binding of DNA to the C-terminal domain of p53 by acetylation. Structure 2005, 13:629-636.
54. Woods D.B., Vousden K.H. Regulation of p53 function. Exp. Cell Res. 2001, 264:56-66.
55. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
56. Vousden K.H., Prives C. Blinded by the light: the growing complexity of p53. Cell 2009, 137:413-431.
57. Robles A.I., Bemmels N.A., Foraker A.B., Harris C.C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001, 61:6660-6664.
58. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T., Roth J.A., Deisseroth A.B., Zhang W.W., Kruzel E., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 1995, 15:3032-3040.
59. Liu X.G., Yue P., Khuri F.R., Sun S.Y. P53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004, 64:5078-5083.
60. Wu G.S., Burns T.F., McDonald E.R., Jiang W., Meng R., Krantz I.D., Kao G., Gan D.D., Zhou J.Y., Muschel R., Hamilton S.R., Spinner N.B., Markowitz S., Wu G., ElDeiry W.S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 1997, 17:141-143.
61. Takimoto R., El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene 2000, 19:1735-1743.
62. Oda K., Arakawa H., Tanaka T., Matsuda K., Tanikawa C., Mori T., Nishimori H., Tamai K., Tokino T., Nakamura Y., Taya Y. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862.
63. Du C., Fang M., Li Y., Li L., Wang X., Smac A mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 2000, 102:33-42.
64. Henry H., Thomas A., Shen Y., White E. Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene 2002, 21:748-760.
65. Attardi L.D., Reczek E.E., Cosmas C., Demicco E.G., McCurrach M.E., Lowe S.W., Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 2000, 14:704-718.
66. Lin Y., Ma W., Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat. Genet. 2000, 26:122-127.
67. Bourdon J.C., Renzing J., Robertson P.L., Fernandes K.N., Lane D.P. Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane. J. Cell Biol. 2002, 158:235-246.
68. Zhao X., Ayer R.E., Davis S.L., Ames S.J., Florence B., Torchinsky C., Liou J.S., Shen L., Spanjaard R.A. Apoptosis factor EI24/PIG8 is a novel endoplasmic reticulum-localized Bcl-2-binding protein which is associated with suppression of breast cancer invasiveness. Cancer Res. 2005, 65:2125-2129.
69. Liu G., Chen X. The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis. Oncogene 2002, 21:7195-7204.
70. Chipuk J.E., Kuwana T., Bouchier-Hayes L., Droin N.M., Newmeyer D.D., Schuler M., Green D.R. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
71. Leu J.I., Dumont P., Hafey M., Murphy M.E., George D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6:443-450.
72. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U.M. P53 has a direct apoptogenic role at the mitochondria. Mol. Cell 2003, 11:577-590.
73. Sansome C., Zaika A., Marchenko N.D., Moll U.M. Hypoxia death stimulus induces translocation of p53 protein to mitochondria - detection by immunofluorescence on whole cells. FEBS Lett. 2001, 488:110-115.
74. Fuster J.J., Sanz-Gonzalez S.M., Moll U.M., Andres V. Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol. Med. 2007, 13:192-199.
75. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol. 2010, 20:14-24.
76. de Almodovar C.R., Ruiz-Ruiz C., Rodriguez A., Ortiz-Ferron G., Redondo J.M., Lopez-Rivas A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) decoy receptor TRAIL-R3 is up-regulated by p53 in breast tumor cells through a mechanism involving an intronic p53-binding site. J. Biol. Chem. 2004, 279:4093-4101.
77. Liu X.G., Yue P., Khuri F.R., Sun S.Y. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity. Cancer Res. 2005, 65:9169-9175.
78. Deb S.P., Munoz R.M., Brown D.R., Subler M.A., Deb S. Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene 1994, 9:1341-1349.
79. Scholl F.A., McLoughlin P., Ehler E., de Giovanni C., Schafer B.W. DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J. Cell Biol. 2000, 151:495-505.
80. Janicke R.U., Sohn D., Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008, 15:959-976.
81. Vaziri H., West M.D., Allsopp R.C., Davison T.S., Wu Y.S., Arrowsmith C.H., Poirier G.G., Benchimol S. ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. EMBO J. 1997, 16:6018-6033.
82. Kim E., Giese A., Deppert W. Wild-type p53 in cancer cells: when a guardian turns into a blackguard. Biochem. Pharmacol. 2009, 77:11-20.
83. Sengupta S., Harris C.C. P53: traffic cop at the crossroads of DNA repair and recombination. Nat. Rev. Mol. Cell Biol. 2005, 6:44-55.
84. Gatz S.A., Wiesmuller L. P53 in recombination and repair. Cell Death Differ. 2006, 13:1003-1016.
85. Wiman K.G. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ. 2006, 13:921-926.
86. Selivanova G., Wiman K.G. Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007, 26:2243-2254.
87. Vousden K.H., Prives C. P53 and prognosis: new insights and further complexity. Cell 2005, 120:7-10.
88. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutat. 2007, 28:622-629.
89. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutat. 2002, 19:607-614.
90. Petitjean A., Achatz M.I., Borresen-Dale A.L., Hainaut P., Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26:2157-2165.
91. Inga A., Storici F., Darden T.A., Resnick M.A. Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol. Cell Biol. 2002, 22:8612-8625.
92. Jegga A.G., Inga A., Menendez D., Aronow B.J., Resnick M.A. Functional evolution of the p53 regulatory network through its target response elements. Proc. Natl. Acad. Sci., USA 2008, 105:944-949.
93. Kato S., Han S.Y., Liu W., Otsuka K., Shibata H., Kanamaru R., Ishioka C. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl. Acad. Sci., USA 2003, 100:8424-8429.
94. Brachmann R.K., Vidal M., Boeke J.D. Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl. Acad. Sci., USA 1996, 93:4091-4095.
95. Scian M.J., Stagliano K.E., Anderson M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., Deb S. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol. Cell Biol. 2005, 25:10097-10110.
96. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., Kamer I., Stambolsky P., Shelly A., Goldfinger N., Valsesia-Wittmann S., Puisieux A., Zundelevich A., Gal-Yam E.N., Avivi C., Barshack I., Brait M., Sidransky D., Domany E., Rotter V. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011, 18:271-281.
97. Krepulat F., Lohler J., Heinlein C., Hermannstadter A., Tolstonog G.V., Deppert W. Epigenetic mechanisms affect mutant p53 transgene expression in WAP-mutp53 transgenic mice. Oncogene 2005, 24:4645-4659.
98. Kalo E., Buganim Y., Shapira K.E., Besserglick H., Goldfinger N., Weisz L., Stambolsky P., Henis Y.I., Rotter V. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II. Mol. Cell Biol. 2007, 27:8228-8242.
99. Stambolsky P., Tabach Y., Fontemaggi G., Weisz L., Maor-Aloni R., Siegfried Z., Shiff I., Kogan I., Shay M., Kalo E., Blandino G., Simon I., Oren M., Rotter V. Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 2010, 17:273-285.
100. Olivier M., Hollstein M., Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2010, 2:a001008.
101. Speidel D., Helmbold H., Deppert W. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. Oncogene 2006, 25:940-953.
102. Kokontis J.M., Wagner A.J., O'Leary M., Liao S., Hay N. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. Oncogene 2001, 20:659-668.
103. Liu Q., El-Deiry W.S., Gazitt Y. Additive effect of Apo2L/TRAIL and Adeno-p53 in the induction of apoptosis in myeloma cell lines. Exp. Hematol. 2001, 29:962-970.
104. Liu Q., Gazitt Y. Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34(+) hematopoietic progenitor cells and normal lymphocytes. Exp. Hematol. 2000, 28:1354-1362.
105. Wang C., Qi R., Li N., Wang Z., An H., Zhang Q., Yu Y., Cao X. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression. J. Biol. Chem. 2009, 284:16183-16190.
106. Selivanova G., Kawasaki T., Ryabchenko L., Wiman K.G. Reactivation of mutant p53: a new strategy for cancer therapy. Semin. Cancer Biol. 1998, 8:369-378.
107. Abarzua P., LoSardo J.E., Gubler M.L., Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53. Cancer Res. 1995, 55:3490-3494.
108. Abarzua P., LoSardo J.E., Gubler M.L., Spathis R., Lu Y.A., Felix A., Neri A. Restoration of the transcription activation function to mutant p53 in human cancer cells. Oncogene 1996, 13:2477-2482.
109. Hupp T.R., Sparks A., Lane D.P. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995, 83:237-245.
110. Niewolik D., Vojtesek B., Kovarik J. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene 1995, 10:881-890.
111. Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B., Grafstrom R.C., Wiman K.G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. 1997, 3:632-638.
112. Shaw P., Freeman J., Bovey R., Iggo R. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus. Oncogene 1996, 12:921-930.
113. Kapoor M., Lozano G. Functional activation of p53 via phosphorylation following DNA damage by UV but not gamma radiation. Proc. Natl. Acad. Sci., USA 1998, 95:2834-2837.
114. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
115. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 2002, 8:282-288.
116. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., Selivanova G. Small molecule RITA binds to p53 blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10:1321-1328.
117. Weinmann L., Wischhusen J., Demma M.J., Naumann U., Roth P., DasMahapatra B., Weller M. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2008, 15:718-729.
118. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
119. Hasegawa H., Yamada Y., Iha H., Tsukasaki K., Nagai K., Atogami S., Sugahara K., Tsuruda K., Ishizaki A., Kamihira S. Activation of p53 by Nutlin-3a, an antagonist of MDM2 induces apoptosis and cellular senescence in adult T-cell leukemia cells. Leukemia 2009, 23:2090-2101.
120. Drakos E., Atsaves V., Schlette E., Li J., Papanastasi I., Rassidakis G.Z., Medeiros L.J. The therapeutic potential of p53 reactivation by nutlin-3a in ALK+ anaplastic large cell lymphoma with wild-type or mutated p53. Leukemia 2009, 23:2290-2299.
121. Hori T., Kondo T., Kanamori M., Tabuchi Y., Ogawa R., Zhao Q.L., Ahmed K., Yasuda T., Seki S., Suzuki K., Kimura T. Nutlin-3 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulation of death receptor 5 (DR5) in human sarcoma HOS cells and human colon cancer HCT116 cells. Cancer Lett. 2010, 287:98-108.
122. Tseng H.Y., Jiang C.C., Croft A., Tay K.H., Thorne R.F., Yang F., Liu H., Hersey P., Zhang X.D. Contrasting effects of Nutlin-3 on TRAIL- and Docetaxel-induced apoptosis due to upregulation of TRAIL-R2 and Mcl-1 in human melanoma cells. Mol. Cancer Ther. 2010, 9:3363-3374.
123. Gravalos C., Garcia-Escobar I., Garcia-Alfonso P., Cassinello J., Malon D., Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin. Transl. Oncol. 2009, 11:526-533.
124. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
125. El-Deiry W.S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001, 8:1066-1075.
126. Tsai W.S., Yeow W.S., Chua A., Reddy R.M., Nguyen D.M., Schrump D.S., Nguyen D.M. Enhancement of Apo2L/TRAIL-mediated cytotoxicity in esophageal cancer cells by cisplatin. Mol. Cancer Ther. 2006, 5:2977-2990.
127. Ehrhardt H., Hacker S., Wittmann S., Maurer M., Borkhardt A., Toloczko A., Debatin K.M., Fulda S., Jeremias I., drug-induced Cytotoxic p53-Mediated upregulation of caspase-8 in tumor cells. Oncogene 2008, 27:783-793.
128. Weekes J., Lam A.K., Sebesan S., Ho Y.H. Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. World J. Gastroenterol. 2009, 15:3597-3602.
129. Clifford B., Beljin M., Stark G.R., Taylor W.R. G2 arrest in response to topoisomerase II inhibitors: the role of p53. Cancer Res. 2003, 63:4074-4081.
130. Wang S., El-Deiry W.S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci., USA 2003, 100:15095-15100.
131. Jesenberger V., Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat. Rev. Mol. Cell Biol. 2002, 3:112-121.
132. Adams J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 2004, 4:349-360.
133. Zhang H.G., Wang J., Yang X., Hsu H.C., Mountz J.D. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004, 23:2009-2015.
134. Chen J.J., Chou C.W., Chang Y.F., Chen C.C. Proteasome inhibitors enhance TRAIL-induced apoptosis through the intronic regulation of DR5: involvement of NF-kappa B and reactive oxygen species-mediated p53 activation. J. Immunol. 2008, 180:8030-8039.
135. Graham B., Gibson S.B. The two faces of NFkappaB in cell survival responses. Cell Cycle 2005, 4:1342-1345.
136. Rayet B., Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene 1999, 18:6938-6947.
137. Shetty S., Gladden J.B., Henson E.S., Hu X., Villanueva J., Haney N., Gibson S.B. Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines. Apoptosis 2002, 7:413-420.
138. Naumann I., Kappler R., von Schweinitz D., Debatin K.M., Fulda S. Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. Clin. Cancer Res. 2011, 17:3204-3218.
139. D'Archivio M., Filesi C., Di Benedetto R., Gargiulo R., Giovannini C., Masella R. Polyphenols, dietary sources and bioavailability. Ann. Ist. Super Sanita 2007, 43:348-361.
140. Murzakhmetova M., Moldakarimov S., Tancheva L., Abarova S., Serkedjieva J. Antioxidant and prooxidant properties of a polyphenol-rich extract from Geranium sanguineum L. In vitro and in vivo. Phytother. Res. 2008, 22:746-751.
141. Lee D.H., Rhee J.G., Lee Y.J. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br. J. Pharmacol. 2009, 157:1189-1202.
142. Kallifatidis G., Rausch V., Baumann B., Apel A., Beckermann B.M., Groth A., Mattern J., Li Z., Kolb A., Moldenhauer G., Altevogt P., Wirth T., Werner J., Schemmer P., Buchler M.W., Salnikov A.V., Herr I. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut 2009, 58:949-963.
143. Chen C.Y., Tai C.J., Cheng J.T., Zheng J.J., Chen Y.Z., Liu T.Z., Yiin S.J., Chern C.L. 6-dehydrogingerdione sensitizes human hepatoblastoma Hep G2 cells to TRAIL-induced apoptosis via reactive oxygen species-mediated increase of DR5. J. Agric. Food Chem. 2010, 58:5604-5611.
144. Shankar S., Chen Q., Siddiqui I., Sarva K., Srivastava R.K. Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3,4',5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential. J. Mol. Signal. 2007, 2:7.
145. Nishino H., Nishino A., Takayasu J., Hasegawa T., Iwashima A., Hirabayashi K., Iwata S., Shibata S. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res. 1988, 48:5210-5215.
146. Laszczyk M.N. Pentacyclic triterpenes of the lupane oleanane and ursane group as tools in cancer therapy. Planta Med. 2009, 75:1549-1560.
147. Gupta S.C., Reuter S., Phromnoi K., Park B., Hema P.S., Nair M., Aggarwal B.B. Nimbolide sensitizes human colon cancer cells to TRAIL through reactive oxygen species- and ERK-dependent up-regulation of death receptors p53 and Bax. J. Biol. Chem. 2011, 286:1134-1146.
148. Zhou J., Lu G.D., Ong C.S., Ong C.N., Shen H.M. Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation. Mol. Cancer Ther. 2008, 7:2170-2180.
149. Herrera E., Barbas C. Vitamin E: action, metabolism and perspectives. J. Physiol. Biochem. 2001, 57:43-56.
150. Zingg J.M., Azzi A. Non-antioxidant activities of vitamin E. Curr. Med. Chem. 2004, 11:1113-1133.
151. Kannappan R., Ravindran J., Prasad S., Sung B.K., Yadav V.R., Reuter S., Chaturvedi M.M., Aggarwal B.B. Gamma-tocotrienol promotes TRAIL-induced apoptosis through reactive oxygen species/extracellular signal-regulated kinase/p53-mediated upregulation of death receptors. Mol. Cancer Ther. 2010, 9:2196-2207.
152. Tomasetti M., Andera L., Alleva R., Borghi B., Neuzil J., Procopio A. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis. FEBS Lett. 2006, 580:1925-1931.
153. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 2002, 41:41-55.
154. Sun S.Y., Yue P., Hong W.K., Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of TRAIL receptors in human lung cancer cells. Cancer Res. 2000, 60:7149-7155.
155. Smith M.L., Kumar M.A. Seleno-l-methionine modulation of nucleotide excision DNA repair relevant to cancer prevention and chemotherapy. Mol. Cell Pharmacol. 2009, 1:218-221.
156. Lin T., Ding Z., Li N., Xu J., Luo G., Liu J., Shen J. Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-kappaB suppression. Eur. J. Cancer 2011, 47:1890-1907.
157. Hu H.B., Jiang C., Schuster T., Li G.X., Daniel P.T., Lu J.X. Inorganic selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway. Mol. Cancer Ther. 2006, 5:1873-1882.
158. Chang M.Y., Ho F.M., Wang J.S., Kang H.C., Chang Y., Ye Z.X., Lin W.W. AICAR induces cyclooxygenase-2 expression through AMP-activated protein kinase-transforming growth factor-beta-activated kinase 1-p38 mitogen-activated protein kinase signaling pathway. Biochem. Pharmacol. 2010, 80:1210-1220.
159. Su R.Y., Chao Y., Chen T.Y., Huang D.Y., Lin W.W. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF alpha-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol. Cancer Ther. 2007, 6:1562-1571.
160. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., Wiman K.G. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 2005, 280:30384-30391.
161. Muret J., Yacoub M., Terrier P., Drusch F., Laplanche A., Gaudin C., Richon C., Le Pechoux C., Le Cesne A., Lejeune F.J., Tursz T., Fouret P., Bonvalot S., Chouaib S. p53 status correlates with histopathological response in patients with soft tissue sarcomas treated using isolated limb perfusion with TNF-alpha and melphalan. Ann. Oncol. 2008, 19:793-800.
162. Li S., Jiang T., Li G., Wang Z. Impact of p53 status to response of temozolomide in low MGMT expression glioblastomas: preliminary results. Neurol. Res. 2008, 30:567-570.
163. Ling X., Calinski D., Chanan-Khan A.A., Zhou M., Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J. Exp. Clin. Cancer Res. 2010, 29:8.
164. Sung B., Park B., Yadav V.R., Aggarwal B.B. Celastrol, a triterpene, Enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010, 285:11498-11507.
165. Goda A.E., Yoshida T., Horinaka M., Yasuda T., Shiraishi T., Wakada M., Sakai T. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008, 27:3435-3445.
166. Su R.Y., Chi K.H., Huang D.Y., Tai M.H., Lin W.W. 15-Deoxy-Delta12,14-prostaglandin J2 up-regulates death receptor 5 gene expression in HCT116 cells: involvement of reactive oxygen species and C/EBP homologous transcription factor gene transcription. Mol. Cancer Ther. 2008, 7:3429-3440.
167. Prasad S., Yadav V.R., Ravindran J., Aggarwal B.B. ROS and CHOP are critical for dibenzylideneacetone to sensitize tumor cells to TRAIL through induction of death receptors and downregulation of cell survival proteins. Cancer Res. 2011, 71:538-549.
168. Tazzari P.L., Tabellini G., Ricci F., Papa V., Bortul R., Chiarini F., Evangelisti C., Martinelli G., Bontadini A., Cocco L., McCubrey J.A., Martelli A.M. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 2008, 68:9394-9403.
169. Zou W., Liu X., Yue P., Zhou Z., Sporn M.B., Lotan R., Khuri F.R., Sun S.Y. c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to inductikon of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3 12-dioxooleana-1 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004, 64:7570-7578.
170. Prasad S., Yadav V.R., Kannappan R., Aggarwal B.B. Ursolic acid, a pentacyclin triterpene, potentiates TRAIL-induced apoptosis through p53-independent up-regulation of death receptors: evidence for the role of reactive oxygen species and JNK. J. Biol. Chem. 2011, 286:5546-5557.
171. Yodkeeree S., Sung B., Limtrakul P., Aggarwal B.B. Zerumbone enhances TRAIL-induced apoptosis through the induction of death receptors in human colon cancer cells: evidence for an essential role of reactive oxygen species. Cancer Res. 2009, 69:6581-6589.
172. Saito S., Takahashi S., Takagaki N., Hirose T., Sakai T. 15-Deoxy-delta(12,14)-prostaglandin J2 induces apoptosis through activation of the CHOP gene in HeLa cells. Biochem. Biophys. Res. Commun. 2003, 311:17-23.
173. Soares A.F., Nosjean O., Cozzone D., D'Orazio D., Becchi M., Guichardant M., Ferry G., Boutin J.A., Lagarde M., Geloen A. Covalent binding of 15-deoxy-delta12 14-prostaglandin J2 to PPARgamma. Biochem. Biophys. Res. Commun. 2005, 337:521-525.
174. Galligan L., Longley D.B., McEwan M., Wilson T.R., McLaughlin K., Johnston P.G. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53 TRAIL receptors and c-FLIP. Mol. Cancer Ther. 2005, 4:2026-2036.
175. Stagni V., Mingardi M., Santini S., Giaccari D., Barila D. ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. Carcinogenesis 2010, 31:1956-1963.
176. Jang J.Y., Jeon Y.K., Choi Y., Kim C.W. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression. Mol. Cancer 2010, 9:262.
177. Yeh C.C., Deng Y.T., Sha D.Y., Hsiao M., Kuo M.Y.P. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther. 2009, 8:2718-2725.
178. Brooks A.D., Ramirez T., Toh U., Onksen J., Elliott P.J., Murphy W.J., Sayers T.J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Tumor. Progress. Therap. Resist. 2005, 1059:160-167.
179. Liu Q., Hilsenbeck S., Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRA. Blood 2003, 101:4078-4087.
180. Sun S.Y., Yue P., Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000, 19:4513-4522.
181. Greco F.A., Bonomi P., Crawford J., Kelly K., Oh Y., Halpern W., Lo L., Gallant G., Klein J. Phase 2 study of mapatumumab a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1 in patients with advanced non-small cell lung cancer. Lung Cancer 2008, 61:82-90.
182. Trarbach T., Moehler M., Heinemann V., Kohne C.H., Przyborek M., Schulz C., Sneller V., Gallant G., Kanzler S. Phase II trial of mapatumumab a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1) in patients with refractory colorectal cancer. Br. J. Cancer 2010, 102:506-512.
183. Mom C.H., Verweij J., Oldenhuis C.N.A.M. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study (vol. 15, p. 5584, 2009). Clin. Cancer Res. 2009, 15:6744.
184. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., Lilenbaum R., Johnson D.H. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl. J. Med. 2006, 355:2542-2550.
185. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L., Ross B.D., Rehemtulla A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci., USA 2000, 97:1754-1759.
186. Shankar S., Singh T.R., Chen X., Thakkar H., Firnin J., Srivastava R.K. The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. Int. J. Oncol. 2004, 24:1133-1140.
187. Shankar S., Singh T.R., Srivastava R.K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 2004, 61:35-49.
188. Beurel E., Blivet-Van Eggelpoel M.J., Kornprobst M., Moritz S., Delelo R., Paye F., Housset C., Desbois-Mouthon C. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells. Biochem. Pharmacol. 2009, 77:54-65.
189. Shin E.C., Seong Y.R., Kim C.H., Kim H., Ahn Y.S., Kim K., Kim S.J., Hong S.S., Park J.H. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis and the resistance is abolished by cisplatin. Exp. Mol. Med. 2002, 34:114-122.
190. Cuello M., Ettenberg S.A., Nau M.M., Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 2001, 81:380-390.
191. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 2000, 60:847-853.
192. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000, 6:335-346.
193. Xu L.H., Deng C.S., Zhu Y.Q., Liu S.Q., Liu D.Z. Synergistic antitumor effect of TRAIL and doxorubicin on colon cancer cell line SW480. World J. Gastroenterol. 2003, 9:1241-1245.
194. Tomek S., Koestler W., Horak P., Grunt T., Brodowicz T., Pribill I., Halaschek J., Haller G., Wiltschke C., Zielinski C.C., Krainer M. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur. J. Cancer 2003, 39:1318-1329.
195. Wang S., Ren W., Liu J., Lahat G., Torres K., Lopez G., Lazar A.J., Hayes-Jordan A., Liu K., Bankson J., Hazle J.D., Lev D. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin. Cancer Res. 2010, 16:2591-2604.
196. Dorsey J.F., Mintz A., Tian X.B., Dowling M.L., Plastaras J.P., Dicker D.T., Kao G.D., El-Deiry W.S. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol. Cancer Ther. 2009, 8:3285-3295.
197. Rohn T.A., Wagenknecht B., Roth W., Naumann U., Gulbins E., Krammer P.H., Walczak H., Weller M. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 2001, 20:4128-4137.
198. Dejosez M., Ramp U., Mahotka C., Krieg A., Walczak H., Gabbert H.E., Gerharz C.D. Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan. Cell Death Differ. 2000, 7:1127-1136.
199. Vivo C., Liu W., Broaddus V.C. c-Jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis-inducing ligand plus DNA damage in chemoresistant p53 inactive mesothelioma cells. J. Biol. Chem. 2003, 278:25461-25467.
200. Ravi R., Jain A.J., Schulick R.D., Pham V., Prouser T.S., Allen H., Mayer E.G., Yu H., Pardoll D.M., Ashkenazi A., Bedi A. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res. 2004, 64:9105-9114.
201. Yoo J., Park S.S., Lee Y.J. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells. J. Cell Biochem. 2008, 104:1636-1646.
202. Maduro J.H., de Vries E.G., Meersma G.J., Hougardy B.M., van der Zee A.G., de Jong S. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:543-552.
203. Nakata S., Yoshida T., Horinaka M., Shiraishi T., Wakada M., Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-6271.
204. Ravi R., Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res. 2002, 62:4180-4185.
205. Rokhlin O.W., Guseva N.V., Taghiyev A.F., Glover R.A., Cohen M.B. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol. Ther. 2010, 9:224-235.
206. Hougardy B.M.T., Maduro J.H., van der Zee A.G.J., de Groot D.J.A., van den Heuvel F.A.J., de Vries E.G.E., de Jong S. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int. J. Cancer 2006, 118:1892-1900.
207. Woods D.C., Liu H.K., Nishi Y., Yanase T., Johnson A.L. Inhibition of proteasome activity sensitizes human granulosa tumor cells to TRAIL-induced cell death. Cancer Lett. 2008, 260:20-27.
208. Roth P., Kissel M., Herrmann C., Eisele G., Leban J., Weller M., Schmidt F. SC68896 a novel small molecule proteasome inhibitor exerts antiglioma activity in vitro and in vivo. Clin. Cancer Res. 2009, 15:6609-6618.
209. Siegelin M.D., Gaiser T., Habel A., Siegelin Y. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Cancer Lett. 2009, 283:230-238.
210. Hasegawa H., Yamada Y., Komiyama K., Hayashi M., Ishibashi M., Yoshida T., Sakai T., Koyano T., Kam T.S., Murata K., Sugahara K., Tsuruda K., Akamatsu N., Tsukasaki K., Masuda M., Takasu N., Kamihira S. Dihydroflavonol BB-1 an extract of natural plant Blumea balsamifera abrogates TRAIL resistance in leukemia cells. Blood 2006, 107:679-688.
211. Prasad S., Ravindran J., Sung B., Pandey M.K., Aggarwal B.B. Garcinol potentiates TRAIL-induced apoptosis through modulation of death receptors and antiapoptotic proteins. Mol. Cancer Ther. 2010, 9:856-868.
212. Fulda S., Debatin K.M. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res. 2004, 64:337-346.
213. Matsui T., Sowa Y., Yoshida T., Murata H., Horinaka M., Wakada M., Nakanishi R., Sakabe T., Kubo T., Sakai T. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis 2006, 27:1768-1777.
214. Frese-Schaper M., Schardt J.A., Sakai T., Carboni G.L., Schmid R.A., Frese S. Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett. 2010, 584:2867-2871.
215. Yoshida T., Shiraishi T., Horinaka M., Nakata S., Yasuda T., Goda A.E., Wakada M., Mizutani Y., Miki T., Nishikawa A., Sakai T. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci. 2007, 98:1417-1423.
216. Liu H., Jiang C.C., Lavis C.J., Croft A., Dong L., Tseng H.Y., Yang F., Tay K.H., Hersey P., Zhang X.D. 2-Deoxy-d-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Mol. Cancer 2009, 8:122.
217. Fecker L.F., Stockfleth E., Braun F.K., Rodust P.M., Schwarz C., Kohler A., Leverkus M., Eberle J. Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP. J. Invest. Dermatol. 2010, 130:2098-2109.